Dianthus Therapeutics, Inc. (DNTH) 10-Year Financial Performance & Capital Metrics

DNTH • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutDianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.Show more

Revenue $6M +120.6%
EBITDA -$101M -112.2%
Net Income -$85M -95.1%
EPS (Diluted) -2.55 +69.8%
Gross Margin 100%
EBITDA Margin -1627.14% +3.8%
Operating Margin -1633.75% +4.2%
Net Margin -1362.77% +11.6%
ROE -32.6% +9.2%
ROIC -41.49% +44.8%
Debt/Equity 0.00 +22.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y61.65%

TTM-42.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-88.32%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.53%

ROCE

10Y Avg-55.83%

5Y Avg-32.48%

3Y Avg-33.85%

Latest-38.78%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	1.48M	6.42M	2.83M	6.24M
Revenue Growth %	-	-	-	-	-	-	3.35%	-0.56%	1.21%
Cost of Goods Sold+	6K	376K	875K	1.84M	1.98M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-6K	-376K	-875K	-1.84M	-1.98M	1.48M	6.42M	2.83M	6.24M
Gross Margin %	-	-	-	-	-	1%	1%	1%	1%
Gross Profit Growth %	-	-61.67%	-1.33%	-1.11%	-0.07%	1.75%	3.35%	-0.56%	1.21%
Operating Expenses+	9.26M	35.35M	59.09M	81.13M	76.72M	14.56M	36.12M	51M	108.1M
OpEx % of Revenue	-	-	-	-	-	9.87%	5.63%	18.05%	17.34%
Selling, General & Admin	3.48M	7.45M	17.75M	23.76M	28.09M	1.96M	6.74M	18.16M	24.99M
SG&A % of Revenue	-	-	-	-	-	1.33%	1.05%	6.43%	4.01%
Research & Development	5.78M	27.9M	41.34M	57.37M	48.64M	12.61M	29.38M	32.84M	83.11M
R&D % of Revenue	-	-	-	-	-	8.54%	4.58%	11.62%	13.33%
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income+	-9.27M	-35.73M	-59.96M	-82.97M	-78.7M	-13.09M	-29.7M	-48.17M	-101.86M
Operating Margin %	-	-	-	-	-	-8.87%	-4.63%	-17.05%	-16.34%
Operating Income Growth %	-	-2.85%	-0.68%	-0.38%	0.05%	0.83%	-1.27%	-0.62%	-1.11%
EBITDA+	-9.26M	-35.35M	-59.09M	-81.13M	-76.72M	-13.09M	-29.56M	-47.82M	-101.45M
EBITDA Margin %	-	-	-	-	-	-8.87%	-4.61%	-16.92%	-16.27%
EBITDA Growth %	-	-2.82%	-0.67%	-0.37%	0.05%	0.83%	-1.26%	-0.62%	-1.12%
D&A (Non-Cash Add-back)	6K	376K	875K	1.84M	1.98M	0	147K	355K	412K
EBIT	-9.27M	-35.49M	-57.52M	-76.77M	-74.94M	-13.09M	-29.7M	-48.17M	-101.86M
Net Interest Income+	0	0	0	0	0	100K	1.15M	4.76M	17.36M
Interest Income	0	236K	2.45M	0	3.77M	100K	1.15M	4.76M	17.36M
Interest Expense	163K	0	0	0	3.77M	0	0	0	0
Other Income/Expense	-163K	236K	2.45M	6.2M	3.77M	-23K	1.23M	4.62M	16.89M
Pretax Income+	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-13.11M	-28.48M	-43.55M	-84.97M
Pretax Margin %	-	-	-	-	-	-8.88%	-4.44%	-15.41%	-13.63%
Income Tax+	0	236K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-13.11M	-28.48M	-43.55M	-84.97M
Net Margin %	-	-	-	-	-	-8.88%	-4.44%	-15.41%	-13.63%
Net Income Growth %	-	-2.76%	-0.62%	-0.33%	0.02%	0.83%	-1.17%	-0.53%	-0.95%
Net Income (Continuing)	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-13.11M	-28.48M	-43.55M	-84.97M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.27	-16.05	-27.62	-33.18	-27.30	-3.82	-7.60	-8.45	-2.55
EPS Growth %	-	-2.76%	-0.72%	-0.2%	0.18%	0.86%	-0.99%	-0.11%	0.7%
EPS (Basic)	-4.27	-16.05	-27.62	-33.18	-27.30	-3.82	-7.60	-8.45	-2.55
Diluted Shares Outstanding	2.21M	2.21M	2.08M	2.31M	2.75M	3.43M	3.75M	5.15M	33.31M
Basic Shares Outstanding	2.21M	2.21M	2.08M	2.31M	2.75M	3.43M	3.75M	5.15M	33.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.83M	52.5M	145.32M	149.84M	151.53M	180.69M	82.03M	177.45M	280.9M
Cash & Short-Term Investments	4.54M	51.57M	142.57M	145.73M	148.84M	176.93M	75.49M	173.72M	275.24M
Cash Only	4.54M	51.57M	58.34M	65.07M	58.15M	131.65M	15.37M	132.32M	22.79M
Short-Term Investments	0	0	84.22M	80.66M	90.68M	45.28M	60.13M	41.39M	252.45M
Accounts Receivable	6.25M	0	0	0	0	0	5.64M	478K	807K
Days Sales Outstanding	-	-	-	-	-	-	320.69	61.74	47.24
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	41K	936K	2.75M	4.11M	2.69M	3.77M	53K	504K	355K
Total Non-Current Assets+	508K	1.96M	11.99M	11.67M	10.09M	9.24M	1.08M	1.95M	93.1M
Property, Plant & Equipment	508K	1.74M	3.07M	9.89M	8.31M	7.46M	956K	800K	1.75M
Fixed Asset Turnover	-	-	-	-	-	0.20x	6.71x	3.53x	3.57x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	218K	8.92M	1.78M	1.78M	1.78M	0	0	81.73M
Other Non-Current Assets	0	4K	0	0	0	0	121K	1.15M	9.63M
Total Assets+	11.34M	54.46M	157.31M	161.51M	161.62M	189.93M	83.11M	179.41M	374.01M
Asset Turnover	-	-	-	-	-	0.01x	0.08x	0.02x	0.02x
Asset Growth %	-	3.8%	1.89%	0.03%	0%	0.18%	-0.56%	1.16%	1.08%
Total Current Liabilities+	2.3M	4.14M	10.42M	14.12M	11.43M	10.86M	8.22M	9.63M	18.45M
Accounts Payable	1.67M	167K	3.49M	2.81M	3.76M	3.04M	1.17M	2.61M	4.58M
Days Payables Outstanding	101.41K	162.11	1.46K	556.91	693.83	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	320K
Deferred Revenue (Current)	0	0	0	0	0	0	100K	100K	479K
Other Current Liabilities	127K	2.65M	4.4M	8.06M	4.56M	4.48M	2.08M	5.36M	13.07M
Current Ratio	4.71x	12.68x	13.95x	10.62x	13.26x	16.63x	9.97x	18.42x	15.22x
Quick Ratio	4.71x	12.68x	13.95x	10.62x	13.26x	16.63x	9.97x	18.42x	15.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	1.25M	6.21M	6.28M	6.4M	1.23M	904K	3.08M
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	438K	168K	1.17M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	1.25M	6.21M	6.28M	6.4M	0	0	0
Total Liabilities	2.3M	4.14M	11.66M	20.32M	17.71M	17.26M	9.45M	10.54M	21.53M
Total Debt+	0	0	0	0	0	0	788K	585K	1.49M
Net Debt	-4.54M	-51.57M	-58.34M	-65.07M	-58.15M	-131.65M	-14.58M	-131.74M	-21.3M
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-56.86x	-	-	-	-20.90x	-	-	-	-
Total Equity+	9.04M	50.32M	145.65M	141.19M	143.91M	172.67M	73.66M	168.87M	352.48M
Equity Growth %	-	4.57%	1.89%	-0.03%	0.02%	0.2%	-0.57%	1.29%	1.09%
Book Value per Share	4.09	22.76	69.95	61.03	52.42	50.28	19.66	32.77	10.58
Total Shareholders' Equity	9.04M	50.32M	145.65M	141.19M	143.91M	172.67M	73.66M	168.87M	352.48M
Common Stock	3K	6K	33K	39K	49K	59K	0	15K	31K
Retained Earnings	-9.72M	-45.21M	-102.73M	-179.5M	-254.43M	-325.57M	-45.87M	-89.42M	-174.39M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-6K	-382K	-8K	8K	-23K	-30K	-161K	47K	106K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.53M	-22.26M	-41.89M	-57.1M	-64.02M	-59.53M	-29.07M	-36.86M	-78.18M
Operating CF Margin %	-	-	-	-	-	-40.33%	-4.53%	-13.04%	-12.54%
Operating CF Growth %	-	-2.41%	-0.88%	-0.36%	-0.12%	0.07%	0.51%	-0.27%	-1.12%
Net Income	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-71.14M	-28.48M	-43.55M	-84.97M
Depreciation & Amortization	6K	376K	875K	1.84M	1.98M	2.02M	147K	355K	412K
Stock-Based Compensation	662K	2.26M	0	0	0	0	1.52M	2.9M	12.89M
Deferred Taxes	0	0	0	-13.54M	-12.95M	0	0	-661K	0
Other Non-Cash Items	306K	13.41M	10.02M	22.53M	23.07M	11.11M	-606K	-762K	-6.17M
Working Capital Changes	1.6M	1.32M	3.98M	8.83M	-1.19M	-1.53M	-1.65M	4.86M	-351K
Change in Receivables	0	0	0	0	0	0	-4.16M	5.16M	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	1.01M	-1.13M	2.5M	145K	948K	-720K	2.28M	661K	8.19M
Cash from Investing+	-139K	-2.2M	-91.7M	1.53M	-10.63M	43.43M	-59.82M	20.25M	-286.81M
Capital Expenditures	-139K	-2.2M	-7.67M	-3.06M	-400K	-1.26M	-139K	-110K	-105K
CapEx % of Revenue	-	-	-	-	-	0.86%	0.02%	0.04%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-135K	12K	0	0	0	0	0	0
Cash from Financing+	10.71M	71.49M	142.15M	62.3M	67.74M	89.6M	96.68M	133.57M	255.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	-3.32M	61.57M	-13.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.67M	-24.46M	-49.56M	-60.16M	-64.42M	-60.8M	-29.21M	-36.97M	-78.28M
FCF Margin %	-	-	-	-	-	-41.19%	-4.55%	-13.08%	-12.56%
FCF Growth %	-	-2.67%	-1.03%	-0.21%	-0.07%	0.06%	0.52%	-0.27%	-1.12%
FCF per Share	-3.02	-11.07	-23.80	-26.01	-23.47	-17.70	-7.79	-7.17	-2.35
FCF Conversion (FCF/Net Income)	0.69x	0.63x	0.73x	0.74x	0.85x	4.54x	1.02x	0.85x	0.92x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-104.3%	-119.57%	-58.7%	-53.53%	-52.57%	-8.28%	-23.12%	-35.92%	-32.6%
Return on Invested Capital (ROIC)	-	-1647.42%	-104.52%	-76.15%	-72.93%	-15.48%	-44.51%	-75.11%	-41.49%
Gross Margin	-	-	-	-	-	100%	100%	100%	100%
Net Margin	-	-	-	-	-	-888.14%	-443.76%	-1541.22%	-1362.77%
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x
Interest Coverage	-56.86x	-	-	-	-20.90x	-	-	-	-
FCF Conversion	0.69x	0.63x	0.73x	0.74x	0.85x	4.54x	1.02x	0.85x	0.92x
Revenue Growth	-	-	-	-	-	-	334.76%	-55.96%	120.63%

Revenue by Segment

	2024
License	326K
License Growth	-

Frequently Asked Questions

Growth & Financials

Dianthus Therapeutics, Inc. (DNTH) reported $3.1M in revenue for fiscal year 2024.

Dianthus Therapeutics, Inc. (DNTH) grew revenue by 120.6% over the past year. This is strong growth.

Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $126.3M for fiscal year 2024.

Dividend & Returns

Dianthus Therapeutics, Inc. (DNTH) has a return on equity (ROE) of -32.6%. Negative ROE indicates the company is unprofitable.

Dianthus Therapeutics, Inc. (DNTH) had negative free cash flow of $109.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Dianthus Therapeutics, Inc. (DNTH) 10-Year Financial Performance & Capital Metrics

DNTH • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $6M +120.6%
EBITDA -$101M -112.2%
Net Income -$85M -95.1%
EPS (Diluted) -2.55 +69.8%
Gross Margin 100%
EBITDA Margin -1627.14% +3.8%
Operating Margin -1633.75% +4.2%
Net Margin -1362.77% +11.6%
ROE -32.6% +9.2%
ROIC -41.49% +44.8%
Debt/Equity 0.00 +22.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y61.65%

TTM-42.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-88.32%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.53%

ROCE

10Y Avg-55.83%

5Y Avg-32.48%

3Y Avg-33.85%

Latest-38.78%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	1.48M	6.42M	2.83M	6.24M
Revenue Growth %	-	-	-	-	-	-	3.35%	-0.56%	1.21%
Cost of Goods Sold+	6K	376K	875K	1.84M	1.98M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-6K	-376K	-875K	-1.84M	-1.98M	1.48M	6.42M	2.83M	6.24M
Gross Margin %	-	-	-	-	-	1%	1%	1%	1%
Gross Profit Growth %	-	-61.67%	-1.33%	-1.11%	-0.07%	1.75%	3.35%	-0.56%	1.21%
Operating Expenses+	9.26M	35.35M	59.09M	81.13M	76.72M	14.56M	36.12M	51M	108.1M
OpEx % of Revenue	-	-	-	-	-	9.87%	5.63%	18.05%	17.34%
Selling, General & Admin	3.48M	7.45M	17.75M	23.76M	28.09M	1.96M	6.74M	18.16M	24.99M
SG&A % of Revenue	-	-	-	-	-	1.33%	1.05%	6.43%	4.01%
Research & Development	5.78M	27.9M	41.34M	57.37M	48.64M	12.61M	29.38M	32.84M	83.11M
R&D % of Revenue	-	-	-	-	-	8.54%	4.58%	11.62%	13.33%
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income+	-9.27M	-35.73M	-59.96M	-82.97M	-78.7M	-13.09M	-29.7M	-48.17M	-101.86M
Operating Margin %	-	-	-	-	-	-8.87%	-4.63%	-17.05%	-16.34%
Operating Income Growth %	-	-2.85%	-0.68%	-0.38%	0.05%	0.83%	-1.27%	-0.62%	-1.11%
EBITDA+	-9.26M	-35.35M	-59.09M	-81.13M	-76.72M	-13.09M	-29.56M	-47.82M	-101.45M
EBITDA Margin %	-	-	-	-	-	-8.87%	-4.61%	-16.92%	-16.27%
EBITDA Growth %	-	-2.82%	-0.67%	-0.37%	0.05%	0.83%	-1.26%	-0.62%	-1.12%
D&A (Non-Cash Add-back)	6K	376K	875K	1.84M	1.98M	0	147K	355K	412K
EBIT	-9.27M	-35.49M	-57.52M	-76.77M	-74.94M	-13.09M	-29.7M	-48.17M	-101.86M
Net Interest Income+	0	0	0	0	0	100K	1.15M	4.76M	17.36M
Interest Income	0	236K	2.45M	0	3.77M	100K	1.15M	4.76M	17.36M
Interest Expense	163K	0	0	0	3.77M	0	0	0	0
Other Income/Expense	-163K	236K	2.45M	6.2M	3.77M	-23K	1.23M	4.62M	16.89M
Pretax Income+	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-13.11M	-28.48M	-43.55M	-84.97M
Pretax Margin %	-	-	-	-	-	-8.88%	-4.44%	-15.41%	-13.63%
Income Tax+	0	236K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-13.11M	-28.48M	-43.55M	-84.97M
Net Margin %	-	-	-	-	-	-8.88%	-4.44%	-15.41%	-13.63%
Net Income Growth %	-	-2.76%	-0.62%	-0.33%	0.02%	0.83%	-1.17%	-0.53%	-0.95%
Net Income (Continuing)	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-13.11M	-28.48M	-43.55M	-84.97M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.27	-16.05	-27.62	-33.18	-27.30	-3.82	-7.60	-8.45	-2.55
EPS Growth %	-	-2.76%	-0.72%	-0.2%	0.18%	0.86%	-0.99%	-0.11%	0.7%
EPS (Basic)	-4.27	-16.05	-27.62	-33.18	-27.30	-3.82	-7.60	-8.45	-2.55
Diluted Shares Outstanding	2.21M	2.21M	2.08M	2.31M	2.75M	3.43M	3.75M	5.15M	33.31M
Basic Shares Outstanding	2.21M	2.21M	2.08M	2.31M	2.75M	3.43M	3.75M	5.15M	33.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.83M	52.5M	145.32M	149.84M	151.53M	180.69M	82.03M	177.45M	280.9M
Cash & Short-Term Investments	4.54M	51.57M	142.57M	145.73M	148.84M	176.93M	75.49M	173.72M	275.24M
Cash Only	4.54M	51.57M	58.34M	65.07M	58.15M	131.65M	15.37M	132.32M	22.79M
Short-Term Investments	0	0	84.22M	80.66M	90.68M	45.28M	60.13M	41.39M	252.45M
Accounts Receivable	6.25M	0	0	0	0	0	5.64M	478K	807K
Days Sales Outstanding	-	-	-	-	-	-	320.69	61.74	47.24
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	41K	936K	2.75M	4.11M	2.69M	3.77M	53K	504K	355K
Total Non-Current Assets+	508K	1.96M	11.99M	11.67M	10.09M	9.24M	1.08M	1.95M	93.1M
Property, Plant & Equipment	508K	1.74M	3.07M	9.89M	8.31M	7.46M	956K	800K	1.75M
Fixed Asset Turnover	-	-	-	-	-	0.20x	6.71x	3.53x	3.57x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	218K	8.92M	1.78M	1.78M	1.78M	0	0	81.73M
Other Non-Current Assets	0	4K	0	0	0	0	121K	1.15M	9.63M
Total Assets+	11.34M	54.46M	157.31M	161.51M	161.62M	189.93M	83.11M	179.41M	374.01M
Asset Turnover	-	-	-	-	-	0.01x	0.08x	0.02x	0.02x
Asset Growth %	-	3.8%	1.89%	0.03%	0%	0.18%	-0.56%	1.16%	1.08%
Total Current Liabilities+	2.3M	4.14M	10.42M	14.12M	11.43M	10.86M	8.22M	9.63M	18.45M
Accounts Payable	1.67M	167K	3.49M	2.81M	3.76M	3.04M	1.17M	2.61M	4.58M
Days Payables Outstanding	101.41K	162.11	1.46K	556.91	693.83	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	320K
Deferred Revenue (Current)	0	0	0	0	0	0	100K	100K	479K
Other Current Liabilities	127K	2.65M	4.4M	8.06M	4.56M	4.48M	2.08M	5.36M	13.07M
Current Ratio	4.71x	12.68x	13.95x	10.62x	13.26x	16.63x	9.97x	18.42x	15.22x
Quick Ratio	4.71x	12.68x	13.95x	10.62x	13.26x	16.63x	9.97x	18.42x	15.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	1.25M	6.21M	6.28M	6.4M	1.23M	904K	3.08M
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	438K	168K	1.17M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	1.25M	6.21M	6.28M	6.4M	0	0	0
Total Liabilities	2.3M	4.14M	11.66M	20.32M	17.71M	17.26M	9.45M	10.54M	21.53M
Total Debt+	0	0	0	0	0	0	788K	585K	1.49M
Net Debt	-4.54M	-51.57M	-58.34M	-65.07M	-58.15M	-131.65M	-14.58M	-131.74M	-21.3M
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-56.86x	-	-	-	-20.90x	-	-	-	-
Total Equity+	9.04M	50.32M	145.65M	141.19M	143.91M	172.67M	73.66M	168.87M	352.48M
Equity Growth %	-	4.57%	1.89%	-0.03%	0.02%	0.2%	-0.57%	1.29%	1.09%
Book Value per Share	4.09	22.76	69.95	61.03	52.42	50.28	19.66	32.77	10.58
Total Shareholders' Equity	9.04M	50.32M	145.65M	141.19M	143.91M	172.67M	73.66M	168.87M	352.48M
Common Stock	3K	6K	33K	39K	49K	59K	0	15K	31K
Retained Earnings	-9.72M	-45.21M	-102.73M	-179.5M	-254.43M	-325.57M	-45.87M	-89.42M	-174.39M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-6K	-382K	-8K	8K	-23K	-30K	-161K	47K	106K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.53M	-22.26M	-41.89M	-57.1M	-64.02M	-59.53M	-29.07M	-36.86M	-78.18M
Operating CF Margin %	-	-	-	-	-	-40.33%	-4.53%	-13.04%	-12.54%
Operating CF Growth %	-	-2.41%	-0.88%	-0.36%	-0.12%	0.07%	0.51%	-0.27%	-1.12%
Net Income	-9.43M	-35.49M	-57.52M	-76.77M	-74.94M	-71.14M	-28.48M	-43.55M	-84.97M
Depreciation & Amortization	6K	376K	875K	1.84M	1.98M	2.02M	147K	355K	412K
Stock-Based Compensation	662K	2.26M	0	0	0	0	1.52M	2.9M	12.89M
Deferred Taxes	0	0	0	-13.54M	-12.95M	0	0	-661K	0
Other Non-Cash Items	306K	13.41M	10.02M	22.53M	23.07M	11.11M	-606K	-762K	-6.17M
Working Capital Changes	1.6M	1.32M	3.98M	8.83M	-1.19M	-1.53M	-1.65M	4.86M	-351K
Change in Receivables	0	0	0	0	0	0	-4.16M	5.16M	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	1.01M	-1.13M	2.5M	145K	948K	-720K	2.28M	661K	8.19M
Cash from Investing+	-139K	-2.2M	-91.7M	1.53M	-10.63M	43.43M	-59.82M	20.25M	-286.81M
Capital Expenditures	-139K	-2.2M	-7.67M	-3.06M	-400K	-1.26M	-139K	-110K	-105K
CapEx % of Revenue	-	-	-	-	-	0.86%	0.02%	0.04%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-135K	12K	0	0	0	0	0	0
Cash from Financing+	10.71M	71.49M	142.15M	62.3M	67.74M	89.6M	96.68M	133.57M	255.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	-3.32M	61.57M	-13.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.67M	-24.46M	-49.56M	-60.16M	-64.42M	-60.8M	-29.21M	-36.97M	-78.28M
FCF Margin %	-	-	-	-	-	-41.19%	-4.55%	-13.08%	-12.56%
FCF Growth %	-	-2.67%	-1.03%	-0.21%	-0.07%	0.06%	0.52%	-0.27%	-1.12%
FCF per Share	-3.02	-11.07	-23.80	-26.01	-23.47	-17.70	-7.79	-7.17	-2.35
FCF Conversion (FCF/Net Income)	0.69x	0.63x	0.73x	0.74x	0.85x	4.54x	1.02x	0.85x	0.92x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-104.3%	-119.57%	-58.7%	-53.53%	-52.57%	-8.28%	-23.12%	-35.92%	-32.6%
Return on Invested Capital (ROIC)	-	-1647.42%	-104.52%	-76.15%	-72.93%	-15.48%	-44.51%	-75.11%	-41.49%
Gross Margin	-	-	-	-	-	100%	100%	100%	100%
Net Margin	-	-	-	-	-	-888.14%	-443.76%	-1541.22%	-1362.77%
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x
Interest Coverage	-56.86x	-	-	-	-20.90x	-	-	-	-
FCF Conversion	0.69x	0.63x	0.73x	0.74x	0.85x	4.54x	1.02x	0.85x	0.92x
Revenue Growth	-	-	-	-	-	-	334.76%	-55.96%	120.63%

Revenue by Segment

	2024
License	326K
License Growth	-

Frequently Asked Questions

Growth & Financials

Dianthus Therapeutics, Inc. (DNTH) reported $3.1M in revenue for fiscal year 2024.

Dianthus Therapeutics, Inc. (DNTH) grew revenue by 120.6% over the past year. This is strong growth.

Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $126.3M for fiscal year 2024.

Dividend & Returns

Dianthus Therapeutics, Inc. (DNTH) has a return on equity (ROE) of -32.6%. Negative ROE indicates the company is unprofitable.

Dianthus Therapeutics, Inc. (DNTH) had negative free cash flow of $109.6M in fiscal year 2024, likely due to heavy capital investments.